Peptide therapeutics: current status and future directions
Quick Takeaways Retatrutide is a triple-receptor agonist (GLP-1, GIP, glucagon) delivering superior monotherapy weight loss at 2428.7% over 4868 weeks Cagrilintide targets amylin receptors for satiety and gastric emptying, achieving 10.8% weight loss in 26 weeks as a monotherapy Retatrutide provides broader metabolic benefits, including dramatic improvements in HbA1c, blood pressure, waist circumference, insulin sensitivity, and liver fat normalization No head-to-head trials exist yet, but the mechanistic and clinical data strongly favor Retatrutide for total body recomposition Retatrutide vs Cagrilintide: Side-by-Side Comparison What Makes Retatrutide Different Retatrutide isnt just another GLP-1 receptor agonist
Plotnikov, Binding of Glyprolines to L-Arginine Inverts Its Analgesic and Antiagressogenic Effects, Bull
NAD + flux is maintained in aged mice despite lower tissue concentrations
Cobalequin is an easy-to-administer form of cobalamin supplementation
April 25, 2022